Reported 4 days ago
Scotiabank has raised its price target for Alnylam Pharmaceuticals (ALNY) from $300 to $338, maintaining an Outperform rating. The firm anticipates strong uptake for Amvuttra, a novel treatment for transthyretin amyloid cardiomyopathy, although it expects the drug's momentum to build in the latter half of 2025.
Source: YAHOO